Lack of complete agreement on international guidelines for treatment of type 2 diabetes

250px

Professor John Petrie was an author of a Lancet Diabetes and Endocrinology paper which brings key and influential members of both sides of the argument together to provide clear international guidance.

Positioning of newer drugs in type 2 diabetes care: an expert consensus on the integration of guideline recommendations 

Cardiovascular outcome trials in patients with type 2 diabetes at high cardiovascular risk have led to remarkable advances in our understanding of the effectiveness of GLP-1 receptor agonists and SGLT2 inhibitors to reduce cardiorenal events. In 2019, the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), and European Society of Cardiology (ESC) published updated recommendations for the management of such patients. 

View full paper online here.

Available for download wihin this link

 


First published: 4 December 2020